Top 10 Safest Stocks To Own For 2016

Top 10 Safest Stocks To Own For 2016: Catalyst Pharmaceutical Partners Inc.(CPRX)

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Advisors' Opinion:

• [By Paul Ausick]

  Stocks on the move: Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) is up about 40% at $1.98 after its firdapse drug treatment for certain kinds of muscle weakness was designated a breakthrough therapy by the FDA. Food maker Dean Foods Inc. (NYSE: DF) held a 1-for-2 reverse stock split this morning and the shares are up about 95%, as might be expected.

• [By John Udovich]

  While the Twitter IPO has been grabing everyones attention, biotech IPOs continue to ! dominate both biotech and IPO news with Karyopharm Therapeutics Inc (NASDAQ: KPTI) going public yesterday andRelypsa (NASDAQ: RLYP), TetraLogic Pharmaceuticals (NASDAQ: TLOG), Vital Therapies (NASDAQ: VTL) and Xencor (NASDAQ: XNCR) filing to go public in the near future(despite the sector producing someugly chartsfor the month of October) plusanother small cap called TNI BioTech (OTCMKTS: TNIB) has also been producing a steady flow of news:

  Karyopharm Therapeutics Debuts. Yesterday, small cap Karyopharm Therapeutics, which is working on a drug that aids the bodys natural tumor-suppressing proteins,debuted at the top ofits range to raise $109 million in an upsizedoffering of 6.8 million shares at $16 apiece with shares closing at $16.81. It should be noted that Karyopharm Therapeutics lead drug candidate (Selinexor) is in early-stage clinical trialsand the company lostlost nearly $12.5 million on revenue of $366,000 during the first six months of this year. Biotech IPOs by Region. On an interesting note, Luke Timmerman, the National Biotech Editor of Xconomy, has written agoodarticle tracking biotech or life sciences IPOs by region. By his count, Boston is home to eight of the 45 (18%) of the life sciences IPOs this year (its companies have alsoraised the most money - about $770 million)plusthe New York/northern New Jersey region is also home toeight. San Diegocame in third with six IPOs followed by San Francisco with five while only five of the 45 biotech IPOscame from outside theUS (Three from Israel and two from Europe). However, the above figures may change as by his account, there are 15 additional biotech companies in line to go public. More Biotechs Set IPO Terms. The small cap biotech space is about to be joined by a few new additions as a couple of biotechs file to go publicover the pastweek or so: Relypsa, which is d

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-safest-stocks-to-own-for-2016.html